Oxford Biomedica
Result of Annual General Meeting
Oxford, UK - 28 May 2021: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held at 3pm on 27 May 2021 in Oxford. As proposed in the Notice of AGM, all resolutions were decided by poll vote.
The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Group's website at www.oxb.com
Copies of the document setting out the above resolutions passed at the 2021 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism
On the Record Date (25 May 2021) there were 82,543,197 ordinary shares of 50 pence each in issue, each carrying one vote per share.
|
|
Resolution |
Votes For |
Votes at Chairman's Discretion |
Votes at other proxy Discretion |
Votes Against |
Votes Withheld* |
Total votes cast |
Result |
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary resolutions |
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
1
|
To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2020 |
58,334,279 (99.99%) |
8,574 (0.01%) |
0 |
1,440 (0.00%) |
59,353 |
58,344,293 |
Passed |
|
|
|
|
|
|
|
|
|
|
|
2
|
To receive the Directors' Remuneration Report and the Report of the Auditor on the Remuneration Report for the year ended 31 December 2020 |
57,033,865 (98.72%) |
8,574 (0.01%) |
0 |
731,131 (1.27%) |
630,076 |
57,773,570 |
Passed |
|
|
|
|
|
|
|
|
|
|
|
3
|
To approve the Directors' Remuneration Policy |
46,429,406 (80.94%) |
8,574 (0.01%) |
0 |
10,926,461 (19.05%) |
1,039,205 |
57,364,441 |
Passed |
|
|
|
|
|
|
|
|
|
|
|
4
|
To appoint Dr. Roch Doliveux as a Director. |
57,832,864 (99.04%) |
8,574 (0.01%) |
0 |
554,706 (0.95%) |
7,502 |
58,396,144 |
Passed
|
|
|
|
|
|
|
|
|
|
|
|
5
|
To appoint Professor Dame Kay Davies as a Director |
58,385,668 (99.99) |
8,574 (0.01%) |
0 |
1,640 (0.00%) |
7,764 |
58,395,882 |
Passed |
|
|
|
|
|
|
|
|
|
|
|
6
|
To appoint Dr. Siyamak Rasty as a Director |
58,325,223 (99.88%) |
8,574 (0.01%) |
0 |
62,347 (0.11%) |
7,502 |
58,396,144 |
Passed |
|
|
|
|
|
|
|
|
|
|
|
7
|
To reappoint John Dawson as a Director |
58,194,899 (99.66%) |
8,574 (0.01%) |
0 |
192,871 (0.33%) |
7,302 |
58,396,344 |
Passed |
|
|
|
|
|
|
|
|
|
|
|
8
|
To reappoint Stuart Paynter as a Director |
58,195,041 (99.66%) |
8,574 (0.01%) |
0 |
192,729 (0.33%) |
7,302 |
58,396,344 |
Passed |
|
|
|
|
|
|
|
|
|
|
|
9
|
To reappoint Stuart Henderson as a Director |
55,957,927 (95.84%) |
8,574 (0.01%) |
0 |
2,423,167 (4.15%) |
13,978 |
58,389,668 |
Passed |
|
|
|
|
|
|
|
|
|
|
|
10
|
To reappoint Dr. Heather Preston as a Director |
55,966,994 (95.84%) |
8,574 (0.01%) |
0 |
2,421,352 (4.15%) |
6,726 |
58,396,920 |
Passed
|
|
|
|
|
|
|
|
|
|
|
|
11
|
To reappoint Robert Ghenchev as a Director |
58,193,434 (99.66%) |
8,574 (0.01%) |
0 |
194,336 (0.33%) |
7,302 |
58,396,344 |
Passed
|
|
|
|
|
|
|
|
|
|
|
|
12
|
To reappoint KMPG LLP as auditor |
58,376,747 (99.98%)
|
8,674 (0.01%)
|
0
|
6,633 (0.01%)
|
11,592
|
58,392,054
|
Passed
|
|
|
|
|
|
|
|
|
|
|
|
13
|
To authorise the Directors to agree the remuneration of the auditor |
57,756,307 (99.98%)
|
8,574 (0.01%)
|
0
|
5,556 (0.01%)
|
633,209
|
57,770,437
|
Passed
|
|
|
|
|
|
|
|
|
|
|
|
14
|
To amend the rules of the Oxford Biomedica 2015 Long Term Incentive Plan |
46,776,691 (81.55%)
|
8,574 (0.01%)
|
0
|
10,579,473 (18.44%)
|
1,038,908
|
57,364,738
|
Passed
|
|
|
|
|
|
|
|
|
|
|
|
15
|
To amend the rules of the Oxford Biomedica 2015 Executive Share Option Scheme |
46,773,232 (81.54%)
|
8,574 (0.01%)
|
0
|
10,582,625 (18.45%)
|
10,582,625 (18.45%)
|
57,364,431
|
Passed
|
|
|
|
|
|
|
|
|
|
|
|
16
|
To authorise the Directors to allot shares |
55,826,926 (96.64%)
|
8,574 (0.01%)
|
0
|
1,936,496 (3.35%)
|
631,650
|
57,771,996
|
Passed
|
|
|
Special resolutions |
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
17
|
To authorise the Directors to disapplypre-emption rights |
57,477,832 (99.49%) |
8,574 (0.01%) |
0 |
286,354 (0.50%) |
630,886 |
57,772,760 |
Passed
|
|
|
|
|
|
|
|
|
|
|
|
18
|
To authorise the Directors to further disapply pre-emption rights foracquisitions and specified capital investments
|
57,477,350 (99.49%) |
8,574 (0.01%) |
0 |
286,636 (0.50%) |
631,086 |
57,772,560 |
Passed
|
|
|
|
|
|
|
|
|
|
|
|
19
|
To permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice |
56,393,012 (96.57%) |
8,574 (0.01%) |
0 |
1,996,782 (3.42%) |
5,278 |
58,398,368 |
Passed
|
* A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.
-Ends-
|
Enquiries: |
|
|
Oxford Biomedica plc
John Dawson, Chief Executive Officer Stuart Paynter, Chief Financial Officer Catherine Isted, Head of Corporate Development & IR
|
T: +44 (0)1865 783 000 T: +44 (0)1865 783 000 T: +44 (0)1865 954 161 / E: ir@oxb.com
|
|
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal |
T: +44 (0)20 3709 5700 |
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a three year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 670 people. Further information is available at www.oxb.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
